Isracann Biosciences expects approvals from Israel

The company Isracann Biosciences (WKN: A2PT0E) is pleased to announce that it has received the necessary plant design and land use permits from the Israeli Ministry of Agriculture.

This will allow them to prepare the building permit and award construction contracts for the planned construction “Phase I.”

You can find more information about the cannabis industry and other important news in the cannabis sector in the Hemp.im app and its companion marijuana news website.

Isracann Biosciences expects to begin cultivation in 2020

Before construction can begin, the building project must be approved by the Israeli settlement commissioner and the Israeli Ministry of Health.

These approvals are still pending, but are expected in a few weeks. The company will soon complete the contract award, so it is believed that nothing should stand in the way of construction starting this year. The significant price increases are expected in the coming weeks.

At present, 230,000 square feet of arable land are fully financed so that cultivation can begin as early as the first quarter of 2020. In the first year of production, a turnover of $28 million is already expected.

Israeli company expects quick returns

Canadian cannabis companies are currently valued at 4.9 times their annual turnover. This would mean a rapid increase in Isracann’s shares price, as the company is currently valued at less than two times its annual turnover.

We also expect strong margins and a rapid return on investment due to low cultivation costs of $0.40 per gram of cannabis. This is less than half the cost in Canada.

“Phase I” comprises the production of two Isracann Biosciences plants with a total area of up to 30,000 square meters. Each of the greenhouses is based on a 5,700 square meter floor plan with an estimated annual production capacity of 5,750 kg of dried cannabis flowers.

The facilities will be built to comply with the Israeli Good Agricultural Practices Guidelines (IMC-GAP) and Good Safety Practices Guidelines (IMC-GSP).

Isracann Biosciences competes with IMC Cannabis

The only competitor currently holding an Israeli asset is IMC Cannabis. In the last financing round, the company accumulated capital at a valuation of $130 million.

Isracann Biosciences (WKN: A2PT0E) is currently valued at just $36 million and, therefore, it has considerable catch-up potential.

Some major investors and banks invested $7.5 million (CA$10 million) in Isracann Biosciences (WKN: A2PT0E) at a price of $0.38 (CA$0.51) in the last financing round.

There is the opportunity to enter at a lower price than major investors, at a current price of $0.27 (CA$0.36).

Currently, the company is valued at just $36 million, with over $15 million in cash in the company treasury. Comparable companies in Canada usually have a valuation of over $200 million.

We are therefore firmly convinced that Isracann (WKN: A2PT0E) will climb towards the mark before the end of the year, as the current market capitalization does not reflect a fair valuation in its approach.

__

(Featured image by Robert Bye via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in dgap, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.